8478

Patents office rejects Pfizer’s claim on Sutent

Cipla gets right to make generic version of drug; patents office says Pfizer patent does not involve any inventive step
Comment E-mail Print Share
First Published: Mon, Feb 11 2013. 08 52 PM IST
Patent litigation comes against the backdrop of a string of patent-related cases being fought in different courts related to the amended Indian patent law. Photo: Hindustan Times
Patent litigation comes against the backdrop of a string of patent-related cases being fought in different courts related to the amended Indian patent law. Photo: Hindustan Times
Updated: Wed, Feb 13 2013. 12 56 AM IST
New Delhi: In yet another setback for multinational pharmaceutical companies’ intellectual property rights, the patents office on Monday rejected Pfizer Inc.’s patent claim on Sutent (sunitinib)—a treatment for liver and kidney cancer.
The patent office has granted Cipla Ltd rights to manufacture generic version of the drug on the grounds that Pfizer’s patent does not involve any inventive step. The patent litigation comes against the backdrop of a string of patent-related cases being fought in different courts related to the amended Indian patent law. Among them, a verdict on Novartis AG's case on a patent for its leukemia treatment Glivec (imatinib) is due any day.
This is a corrected version of an earlier story.
Comment E-mail Print Share
First Published: Mon, Feb 11 2013. 08 52 PM IST
More Topics: Pfizer | Sutent | Cipla | patents |
blog comments powered by Disqus
  • Wed, Jul 30 2014. 05 04 PM
  • Wed, Jul 23 2014. 06 06 PM
ALSO READ close

AstraZeneca raises full-year forecast as profit beats estimates

Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved